|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2006-11-19
|
|
pubmed:abstractText |
In previous studies, alemtuzumab demonstrated considerable activity in patients with previously treated B-cell chronic lymphocytic leukemia (CLL), including fludarabine-refractory disease. In this retrospective study, the authors evaluated the benefit of alemtuzumab monotherapy in unselected patients with advanced, previously treated CLL who received treatment in the routine clinical setting.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
pubmed-author:Austrian Collaborative Study Group on Alemtuzumab in Chronic...,
pubmed-author:BauerFranzF,
pubmed-author:BruggerStefanS,
pubmed-author:DemirtasDitaD,
pubmed-author:FalknerAndreasA,
pubmed-author:FieglMichaelM,
pubmed-author:GastlGüntherG,
pubmed-author:GreilRichardR,
pubmed-author:GrossschmidtPeterP,
pubmed-author:HaslbauerFerdinandF,
pubmed-author:HopfingerGeorgG,
pubmed-author:TatzreiterGeorgG,
pubmed-author:ZaberniggAugustA
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
107
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2408-16
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17054106-Aged,
pubmed-meshheading:17054106-Aged, 80 and over,
pubmed-meshheading:17054106-Antibodies, Monoclonal,
pubmed-meshheading:17054106-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17054106-Antibodies, Neoplasm,
pubmed-meshheading:17054106-Antineoplastic Agents,
pubmed-meshheading:17054106-Austria,
pubmed-meshheading:17054106-Disease Progression,
pubmed-meshheading:17054106-Dose-Response Relationship, Drug,
pubmed-meshheading:17054106-Drug Administration Schedule,
pubmed-meshheading:17054106-Female,
pubmed-meshheading:17054106-Humans,
pubmed-meshheading:17054106-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:17054106-Male,
pubmed-meshheading:17054106-Middle Aged,
pubmed-meshheading:17054106-Recurrence,
pubmed-meshheading:17054106-Retrospective Studies,
pubmed-meshheading:17054106-Salvage Therapy,
pubmed-meshheading:17054106-Survival Analysis
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.
|
|
pubmed:affiliation |
Department of Internal Medicine, Division of Hemato-Oncology, University Hospital of Innsbruck, Innsbruck, Austria. michael.fiegl@uibk.ac.at
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Evaluation Studies
|
